Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Contrast-Enhanced Three-Dimensional Pulmonary Perfusion Magnetic Resonance Imaging: Intraindividual Comparison of 1.0 M Gadobutrol and 0.5 M Gd-DTPA at Three Dose Levels

Fink, Christian MD*; Puderbach, Michael MD*; Ley, Sebastian MD*; Plathow, Christian MD*; Bock, Michael PhD; Zuna, Ivan PhD; Kauczor, Hans-Ulrich MD*

doi: 10.1097/01.rli.0000101482.79137.f4
Original Article
Buy

Rationale and Objectives: To compare 1.0 M gadobutrol and 0.5 M Gd-DTPA for contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging (3D MRI).

Materials and Methods: Ten healthy volunteers (3 females; 7 males; median age, 27 years; age range, 18–31 years) were examined with contrast-enhanced dynamic 3D MRI with parallel acquisition technique (FLASH 3D; reconstruction algorithm: generalized autocalibrating partially parallel acquisitions; acceleration factor: 2; TE/TR/α: 0.8/1.9 milliseconds/40°; FOV: 500 × 375 mm; matrix: 256 × 86; slab thickness: 180 mm; 36 partitions; voxel size: 4.4 × 2 × 5 mm3; TA: 1.48 seconds). Twenty-five consecutive data sets were acquired after intravenous injection of 0.025, 0.05, and 0.1 mmol/kg body weight of gadobutrol and Gd-DTPA. Quantitative measurements of peak signal-to-noise ratios (SNR) of both lungs were performed independently by 3 readers. Bolus transit times through the lungs were assessed from signal intensity time curves.

Results: The peak SNR in the lungs was comparable between gadobutrol and Gd-DTPA at all dose levels (15.7 vs. 15.5 at 0.1 mmol/kg bw; 12.9 vs. 12.5 at 0.05 mmol/kg bw; 7.6 vs. 8.9 at 0.025 mmol/kg bw). A dose of 0.1 mmol/kg achieved the highest peak SNR compared with all other dose levels (P < 0.05). A higher peak SNR was observed in gravity dependent lung (P < 0.05). Despite different injection volumes, transit times of the contrast bolus did not differ between both agents.

Conclusion: Higher concentrated gadolinium chelates offer no advantage over standard 0.5 M Gd-DTPA for contrast-enhanced 3D MRI of lung perfusion.

From the *Department of Radiology, †Department Medical Physics in Radiology, and ‡Clinical Cooperation Unit Radiation Oncology, Deutsches Krebsforschungszentrum (DKFZ), Innovative Krebsdiagnostik und Therapie, Heidelberg, Germany.

Received July 2, 2003 and accepted for publication, after revision, September 14, 2003.

Supported by Schering AG, Berlin, Germany

Reprints: Christian Fink, MD, Innovative Krebsdiagnostik und-therapie, Department of Radiology E010, Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. E-mail: c.fink@dkfz.de

© 2004 Lippincott Williams & Wilkins, Inc.